What happened
Harrow, Inc. (NASDAQ: HROW) closed its TYRVAYA acquisition from Viatris Inc. and paid $30 million in cash at closing.
Harrow got worldwide rights to TYRVAYA except Japan. Viatris kept Japan commercialization rights and will pay Harrow royalties on future net sales there.
Harrow expects about 40 experienced Viatris employees to join its Ocular Surface commercial team in the fourth quarter of 2026.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Cash paid at closing | $30 million | SEC 8-K | |
| Contingent milestone payments | up to $70 million | SEC 8-K | |
| Potential total consideration | up to $100 million | SEC Exhibit 99.1 | |
| TYRVAYA revenue expected in 2027 | more than $30 million | SEC Exhibit 99.1 |
Read more: Harrow (HROW) stock analysis and investment case
Why it matters
The deal adds TYRVAYA, a dry eye product and the first and only FDA-approved nasal spray for dry eye disease, to Harrow's VEVYE franchise.
It gives Harrow two branded prescription therapies for the same market, which may widen its commercial reach.
Harrow said TYRVAYA will be available to eyecare professionals through its commercial organization right after closing.
Both brands use PhilRx as their main specialty pharmacy, and Harrow said one Ocular Surface commercial organization will support both products.
OptimistFi's calculation puts the $30 million upfront payment at 30% of the filing's up to $100 million total consideration cap.
The upside still depends on future net sales thresholds through 2029, and the 2027 revenue figure is management guidance rather than a reported result.
Browse: stock research on every company OptimistFi covers
What's next
Harrow said it will onboard the roughly 40 former Viatris employees in the fourth quarter of 2026.
That is the next dated milestone in the filing, and stronger TYRVAYA adoption would support the acquisition case.
The contingent milestone payments use twelve-month measurement periods ending on or before December 31, 2029.
TYRVAYA sales through that date will determine whether any of the $70 million cap is earned.
Harrow also said it will file the Purchase Agreement as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.
Better-than-expected 2027 TYRVAYA revenue would support the acquisition case, while weak sales would leave more of the contingent payment cap untouched.
More from OptimistFi
- HROW stock: the Harrow thesis, its status and the next test to watch
- United States Brent Oil Fund, LP (NYSE Arca: BNO) Tracks a Supply Gap
- Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze
- Meta Platforms, Inc. (NASDAQ: META) Has a Conditional $18 Billion Bill
- Stock research on every company OptimistFi covers
- Latest stock research and investment-case updates
- OptimistFi: evidence-first equity research
Sources
- SEC Exhibit 99.1 press release — Press release announcing the TYRVAYA acquisition closing, Japan rights, 2027 revenue expectation and commercial team plans.
- SEC Form 8-K — Current report describing the completed acquisition, cash consideration, contingent payments and Japan rights.
Read the full OptimistFi thesis on Harrow, Inc.: https://optimistfi.com/stocks/HROW
See what would break the Harrow, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full Harrow, Inc. investment case, its status and the next test to watch live on the Harrow, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
